The Promotive Effects of Antioxidative Apigenin on the Bioavailability of Paclitaxel for Oral Delivery in Rats = The Promotive Effects of Antioxidative Apigenin on the Bioavailability of Paclitaxel for Oral Delivery in Rats

다국어 초록 (Multilingual Abstract)

This study was to investigate the effect of apigenin on the bioavailability of paclitaxel after oral and intravenous administration in rats. The effect of apigenin on P-glycoprotein (P-gp), cytochrome P450 (CYP)3A4 activity was evaluated. The pharmacokinetic parameters of paclitaxel were determined in rats after oral (40 mg/kg) or intravenous (5 mg/kg) administration of paclitaxel with apigenin (0.4, 2 and 8 mg/kg) to rats. Apigenin inhibited CYP3A4 activity with 50% inhibition concentration (IC50) of 1.8 μM. In addition, apigenin significantly inhibited P-gp activity. Compared to the control group, apigenin significantly increased the area under the plasma concentration-time curve (AUC, p＜0.05 by 2 mg/kg, 59.0% higher; p＜0.01 by 8 mg/kg, 87% higher) of oral paclitaxel. Apigenin also significantly (p＜0.05 by 2 mg/kg, 37.2% higher; p＜0.01 by 8 mg/kg, 59.3% higher) increased the peak plasma concentration (Cmax) of oral paclitaxel. Apigenin significantly increased the terminal half-life (t1/2, p＜0.05 by 8 mg/kg, 34.5%) of oral paclitaxel. Consequently, the absolute bioavailability (A.B.) of paclitaxel was significantly (p＜0.05 by 2 mg/kg, p＜0.01 by 8 mg/kg) increased by apigenin compared to that in the control group, and the relative bioavailability (R.B.) of oral paclitaxel was increased by 1.14- to 1.87-fold. The pharmacokinetics of intravenous paclitaxel were not affected by the concurrent use of apigenin in contrast to the oral administration of paclitaxel. Accordingly, the enhanced oral bioavailability by apigenin may be mainly due to increased intestinal absorption caused via P-gp inhibition by apigenin rather than to reduced renal and hepatic elimination of paclitaxel. The increase in the oral bioavailability might be mainly attributed to enhanced absorption in the gastrointestinal tract via the inhibition of P-gp and reduced first-pass metabolism of paclitaxel via the inhibition of the CYP3A subfamily in the small intestine and/or in the liver by apigenin. It appears that the development of oral paclitaxel preparations as a combination therapy is possible, which will be more convenient than the i.v. dosage form.

참고문헌 (Reference)

1 Cao, X, "Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model" 23 : 1675-1686, 2006

2 Sonnichsen, D. S, "Variability in human cytochrome P450 paclitaxel metabolism" 27 : 566-575, 1995

3 Cummins, C. L, "Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4" 300 : 1036-1045, 2002

4 Choi, J. S, "The effect of verapamil on the pharmacokinetics of paclitaxel in rats" 24 : 95-100, 2005

5 Walle, T, "Taxol metabolism and disposition in cancer patients" 23 : 506-512, 1995

6 Fukuda, K, "Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction" 7 : 391-396, 1997

7 Rahman, A, "Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8" 54 : 5543-5546, 1994

8 Lee, S. H, "Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography" 724 : 357-363, 1999

9 Wani, M. C, "Plant antitumor agnets. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia" 93 : 2325-2327, 1971

10 Galati, G, "Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: glutathione oxidation and conjugation" 30 : 370-382, 2001

11 Choi, S. U, "Novel multidrug-resistance modulators, KR-30026 and KR-30031, in cancer cells" 17 : 4577-4582, 1997

12 Critchfield, J. W, "Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism" 48 : 1437-1445, 1994

13 Crespi, C. L, "Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450" 248 : 188-190, 1997

14 Harris, J. W, "Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme" 54 : 4026-4035, 1994

15 Kelly, P. A, "Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4" 24 : 321-328, 1999

16 Sparreboom, A, "Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine" 4 : 2031-2035, 1997

17 Kimura, Y, "Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity" 48 : 429-435, 2010

18 Ho, P. C, "Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds" 4 : 217-227, 2001

19 Dixon, R. A, "Flavonoids and isoflavonoids - a gold mine for metabolic engineering" 4 : 394-400, 1999

20 Gates, M. A, "Flavonoid intake and ovarian cancer risk in a population-based case-control study" 124 : 1918-1925, 2009

21 Choi, J. S, "Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rat" 292 : 149-156, 2005

22 Choi, J. S, "Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin" 57 : 313-318, 2004

23 Woo, J. S, "Enhanced oral bioavailability of paclitaxel by coadministration of the P-gp inhibitor KR30031" 20 : 24-30, 2003

24 van Asperen, J, "Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporine A" 4 : 2293-2297, 1998

25 Li, X, "Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats" 337 : 188-193, 2007

26 Nguyen, H, "Effect of flavonoids on MRP1-mediated transport in Panc-1 cells" 92 : 250-257, 2003

27 Berg, S. L, "Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer" 13 : 2039-2042, 1995

28 Gao, P, "Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability" 92 : 2386-2398, 2003

29 Nafisi, S, "DNA Adducts with Antioxidant Flavonoids: Morin, Apigenin, and Naringin" 27 : 1-10, 2008

30 Lewis,D.F.V, "Cytochrome P450. Substrate specificity and metabolism. In Cytochromes P450. Structure, Function, and Mechanism" Taylor & Francis 122-123, 1996

31 Chuang, C. M, "Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects" 27 : 49-60, 2009

32 Meerum Terwogt, J. M, "Coadministration of oral cyclosporin A enables oral therapy with paclitaxel" 5 : 3379-3384, 1999

33 Rowinsky, E. K, "Clinical toxicities encountered with paclitaxel (Taxol)" 20 : 1-15, 1993

34 Jeong, G. S, "Anti-inflammatory effects of apigenin on nicotineand lipopolysaccharide-stimulated human periodontal ligament cells via heme oxygenase-1" 9 : 1374-1380, 2009

35 Yin, Y, "Anti-inflammatory and immunosuppressive effect of flavones isolated from Artemisia vestita" 120 : 1-6, 2008

36 Choi, B. C, "Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rat" 323 : 81-85, 2006

37 Andreeva, M, "A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum" 19 : 327-332, 1997